IPO13

Summary

IPO13 (importin 13, HGNC:16853) is a protein-coding gene on chromosome 1p34.1, encoding Importin-13 (O94829). Functions in nuclear protein import as nuclear transport receptor. It is a common-essential gene (DepMap: required in 95.6% of cancer cell lines).

This gene encodes a member of the importin-beta family of nuclear transport proteins. The encoded protein mediates the import of specific cargo proteins from the cytoplasm to the nucleus and is dependent on the Ras-related nuclear protein-GTPase system. The encoded protein is also involved in nuclear export of the eukaryotic translation initiation factor 1A.

Source: NCBI Gene 9670 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 119 total
• Cancer dependency (DepMap): dependent in 95.6% of screened cell lines (common-essential)
• MANE Select transcript: NM_014652

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16853
Approved symbol	IPO13
Name	importin 13
Location	1p34.1
Locus type	gene with protein product
Status	Approved
Aliases	IMP13, KIAA0724, RANBP13
Ensembl gene	ENSG00000117408
Ensembl biotype	protein_coding
OMIM	610411
Entrez	9670

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 20 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000372339, ENST00000372343, ENST00000480902, ENST00000486876, ENST00000489061, ENST00000489773, ENST00000492152, ENST00000862660, ENST00000862661, ENST00000862662, ENST00000862663, ENST00000862664, ENST00000862665, ENST00000862666, ENST00000862667, ENST00000862668, ENST00000862669, ENST00000862670, ENST00000862671, ENST00000862672, ENST00000924210, ENST00000924211, ENST00000924212, ENST00000950460, ENST00000950461

RefSeq mRNA: 1 — MANE Select: NM_014652 NM_014652

CCDS: CCDS503

Canonical transcript exons

ENST00000372343 — 20 exons

Exon	Start	End
ENSE00000770139	43949417	43950153
ENSE00000770414	43957977	43958158
ENSE00000770494	43958242	43958268
ENSE00000770562	43958461	43958595
ENSE00000770563	43958746	43958889
ENSE00000770564	43960249	43960329
ENSE00000770576	43961166	43961262
ENSE00000770577	43964269	43964321
ENSE00000770580	43966575	43966641
ENSE00000770582	43966724	43966782
ENSE00000770593	43966930	43967019
ENSE00000770596	43967315	43967496
ENSE00001457579	43967586	43968022
ENSE00001457588	43946950	43947684
ENSE00003238145	43960876	43961013
ENSE00003476490	43957195	43957315
ENSE00003566272	43957402	43957549
ENSE00003618776	43956810	43956976
ENSE00003634948	43956320	43956460
ENSE00003669918	43956560	43956701

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 97.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.0202 / max 450.2358, expressed in 1817 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
2568	23.7496	1817
2567	1.1862	502
2569	0.0844	30

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	97.62	gold quality
gastrocnemius	UBERON:0001388	97.11	gold quality
apex of heart	UBERON:0002098	97.07	gold quality
spinal cord	UBERON:0002240	96.93	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.87	gold quality
muscle of leg	UBERON:0001383	96.05	gold quality
putamen	UBERON:0001874	95.86	gold quality
corpus callosum	UBERON:0002336	95.81	gold quality
inferior vagus X ganglion	UBERON:0005363	95.75	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.75	gold quality
right frontal lobe	UBERON:0002810	95.61	gold quality
lateral globus pallidus	UBERON:0002476	95.57	gold quality
cerebellar hemisphere	UBERON:0002245	95.37	gold quality
cerebellar cortex	UBERON:0002129	95.28	gold quality
olfactory bulb	UBERON:0002264	95.24	silver quality
muscle organ	UBERON:0001630	95.19	gold quality
caudate nucleus	UBERON:0001873	95.17	gold quality
amygdala	UBERON:0001876	95.08	gold quality
nucleus accumbens	UBERON:0001882	95.01	gold quality
subthalamic nucleus	UBERON:0001906	94.83	gold quality
gluteal muscle	UBERON:0002000	94.78	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.51	gold quality
left testis	UBERON:0004533	94.47	gold quality
substantia nigra	UBERON:0002038	94.41	gold quality
lower esophagus mucosa	UBERON:0035834	94.36	gold quality
right testis	UBERON:0004534	94.35	gold quality
midbrain	UBERON:0001891	94.32	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.21	gold quality
cerebellum	UBERON:0002037	94.00	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.60

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CRX, CTCF, PAX3, PAX6

miRNA regulators (miRDB)

26 targeting IPO13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-6513-5P	99.43	67.81	1071
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-4695-5P	99.06	64.87	1151
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-299-5P	98.56	71.14	1140
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-5089-5P	98.45	66.06	1388
HSA-MIR-6815-5P	96.05	65.55	662
HSA-MIR-6865-5P	96.05	65.58	675
HSA-MIR-6726-5P	95.97	63.72	841
HSA-MIR-920	95.97	63.95	811
HSA-MIR-4300	95.85	64.56	1003
HSA-MIR-5591-5P	95.85	64.76	1002
HSA-MIR-6802-5P	94.94	65.95	366
HSA-MIR-135A-3P	94.19	66.09	495

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 95.6% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 16)

• Imp13 functions in myopodin import and the regulation of this event is critical for normal and abnormal cellular differentiation. (PMID:17828378)
• Importin 13 mediates nuclear import of histone fold-containing chromatin accessibility complex heterodimers (PMID:19218565)
• IPO13 is uniquely expressed by human limbal basal epithelial cells, and plays an important role in maintaining the phenotype, high proliferative potential, and less differentiation of corneal epithelial progenitor cells. (PMID:19593795)
• IPO13 variation may improve nuclear bioavailability of endogenous glucocorticoids (PMID:19619331)
• Data show that expression of IPO13, c-kit, telomerase, caspase3, and CD146 are decreased in endometrial polyps; however, the expression of bcl-2 was increased in polyps compared to the normal endometrial tissue. (PMID:21804459)
• These results demonstrate an increased expression of IPO13 in endometriosis and endometrial carcinoma. (PMID:22648251)
• Imp13 is able to bind and export eIF1A in vivo and that its function is essential. (PMID:23435562)
• IPO13 may contribute to the pathogenesis of pterygium via modulation of K17 and c-Jun. (PMID:23559854)
• IPO13 influenced intracellular distribution of CTCF. (PMID:23620300)
• The anti- glucocorticoid receptor effect of respiratory syncytial virus was mediated by viral nonstructural protein 1, which likely functioned by competing with IPO13 for glucocorticoid receptor binding. (PMID:28968829)
• this study significantly expands the repertoire of importin 13 cargoes and sets the basis for a more detailed characterization of this extremely versatile transport receptor. (PMID:29666159)
• This study reports the identification of mutation (c.331C>T, p.R111C) in the IPO13 gene in a consanguineous family with ocular coloboma, microphthalmia, and cataract by a combination of whole-exome sequencing and homozygosity mapping. (PMID:29700284)
• This is the first report that IPO13 can be phosphorylated at Ser193 and that this modification regulates IPO13 subcellular localization and nucleocytoplasmic transport function, with important implications for IPO13’s role in development and other processes. (PMID:30045875)
• Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation. (PMID:33082305)
• Nuclear transporter Importin-13 plays a key role in the oxidative stress transcriptional response. (PMID:34625540)
• The Nuclear Transporter Importin 13 Can Regulate Stress-Induced Cell Death through the Clusterin/KU70 Axis. (PMID:36672214)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ipo13b	ENSDARG00000060618
mus_musculus	Ipo13	ENSMUSG00000033365
rattus_norvegicus	Ipo13	ENSRNOG00000019758
drosophila_melanogaster	cdm	FBGN0261532
caenorhabditis_elegans		WBGENE00011807

Paralogs (1): TNPO3 (ENSG00000064419)

Protein

Protein identifiers

Importin-13 — O94829 (reviewed: O94829)

Alternative names: Karyopherin-13, Ran-binding protein 13

All UniProt accessions (2): O94829, Q5T4X2

UniProt curated annotations — full annotation on UniProt →

Function. Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates the nuclear import of UBC9, the RBM8A/MAGOH complex, PAX6 and probably other members of the paired homeobox family. Also mediates nuclear export of eIF-1A, and the cytoplasmic release of eIF-1A is triggered by the loading of import substrates onto IPO13.

Subunit / interactions. Interacts with UBC9, RAN, RBM8A, eIF-1A and PAX6.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in fetal brain, heart, intestine and kidney.

Similarity. Belongs to the importin beta family.

RefSeq proteins (1): NP_055467* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001494	Importin-beta_N	Domain
IPR011989	ARM-like	Homologous_superfamily
IPR013598	Exportin-1/Importin-b-like	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR040520	Importin_rep_3	Repeat
IPR040709	Importin_rep_1	Repeat
IPR040944	Importin_rep_2	Repeat
IPR051345	Importin_beta-like_NTR	Family
IPR057941	TPR_TNPO3_IPO13_2nd	Repeat
IPR057942	TPR_TNPO3_IPO13_3rd	Repeat
IPR058537	TPR_TNPO3_IPO13_4th	Repeat

Pfam: PF03810, PF08389, PF18773, PF18786, PF18806, PF24138, PF24139, PF24140

UniProt features (98 total): helix 60, repeat 20, turn 12, sequence conflict 3, chain 1, domain 1, strand 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
2X19	X-RAY DIFFRACTION	2.8
2XWU	X-RAY DIFFRACTION	2.8
3ZJY	X-RAY DIFFRACTION	3.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94829-F1	90.60	0.80

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 109 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, RNGTGGGC_UNKNOWN, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GCANCTGNY_MYOD_Q6, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOMF_GTPASE_BINDING, USF_C, GOBP_NUCLEAR_TRANSPORT, BROWNE_HCMV_INFECTION_24HR_UP, MYCMAX_01, chr1p34, ZIC1_01, NRF2_Q4, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE

GO Biological Process (3): protein import into nucleus (GO:0006606), intracellular protein transport (GO:0006886), protein transport (GO:0015031)

GO Molecular Function (2): small GTPase binding (GO:0031267), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
intracellular protein transport	1
protein localization to nucleus	1
import into nucleus	1
establishment of protein localization to organelle	1
protein transport	1
intracellular transport	1
transport	1
establishment of protein localization	1
GTPase binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

916 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IPO13	BAIAP3	O94812	813
IPO13	XPOT	O43592	783
IPO13	XPO4	Q9C0E2	775
IPO13	IPO11	Q9UI26	775
IPO13	IPO9	Q96P70	759
IPO13	IPO7	O95373	735
IPO13	IPO4	Q8TEX9	734
IPO13	ARX	Q96QS3	730
IPO13	IPO5	O00410	722
IPO13	UBE2I	P50550	714
IPO13	IPO8	O15397	707
IPO13	TNPO2	O14787	692
IPO13	SHOX2	O60902	689
IPO13	XPO7	Q9UIA9	674
IPO13	TNPO1	Q92973	673

IntAct

150 interactions, top by confidence:

A	B	Type	Score
PBX4	IPO13	psi-mi:“MI:0915”(physical association)	0.830
IPO13	PBX4	psi-mi:“MI:0915”(physical association)	0.830
IPO13	EIF1AX	psi-mi:“MI:0915”(physical association)	0.750
EIF1AX	IPO13	psi-mi:“MI:0915”(physical association)	0.750
IPO13	EIF1AX	psi-mi:“MI:0407”(direct interaction)	0.750
IPO13	RAN	psi-mi:“MI:0407”(direct interaction)	0.730
RAN	IPO13	psi-mi:“MI:0407”(direct interaction)	0.730
IPO13	RAN	psi-mi:“MI:0915”(physical association)	0.730
IPO13	UBE2I	psi-mi:“MI:0407”(direct interaction)	0.720
UBE2I	IPO13	psi-mi:“MI:0407”(direct interaction)	0.720
IPO13	UBE2I	psi-mi:“MI:0915”(physical association)	0.720
PITX1	IPO13	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (135): PBX4 (Two-hybrid), IPO13 (Affinity Capture-RNA), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Two-hybrid), IPO13 (Two-hybrid), IPO13 (Affinity Capture-Western), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS), IPO13 (Affinity Capture-MS)

ESM2 similar proteins: A0A3L7I2I8, A0JMZ3, A5HK05, A7MB89, A7YWD2, O60733, O75031, O94829, O94955, P0C7A6, P42694, P49754, P97570, P97819, Q05AL1, Q1LVW0, Q29RM5, Q2KI54, Q2T9K6, Q3UFS0, Q3UJZ3, Q4V890, Q5KU39, Q5R6S3, Q5R974, Q5T9G4, Q5TYQ1, Q5VZK9, Q68FK4, Q6DFV5, Q6EDY6, Q6NYU2, Q6QI06, Q6R327, Q7T3P8, Q8C0T1, Q8CEF1, Q8IUR7, Q8NFZ0, Q91W86

Diamond homologs: A7YWD2, O94829, Q5R974, Q5ZIC8, Q8K0C1, Q9JM04

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 126 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	7	8.2×	5e-03
G alpha (q) signalling events	9	7.0×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
phospholipase C-activating G protein-coupled receptor signaling pathway	7	8.9×	6e-03
positive regulation of cytosolic calcium ion concentration	7	7.9×	6e-03
positive regulation of ERK1 and ERK2 cascade	8	6.5×	6e-03
G protein-coupled receptor signaling pathway	14	4.9×	8e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

119 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	94
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

3473 predictions. Top by Δscore:

Variant	Effect	Δscore
1:43956317:TAG:T	acceptor_loss	1.0000
1:43956318:AG:A	acceptor_gain	1.0000
1:43956319:G:GA	acceptor_loss	1.0000
1:43956319:GG:G	acceptor_gain	1.0000
1:43956319:GGT:G	acceptor_gain	1.0000
1:43956319:GGTAC:G	acceptor_gain	1.0000
1:43956446:C:T	donor_gain	1.0000
1:43956457:CCCG:C	donor_loss	1.0000
1:43956459:CGGT:C	donor_loss	1.0000
1:43956460:GGTA:G	donor_loss	1.0000
1:43956461:G:T	donor_loss	1.0000
1:43956462:T:C	donor_loss	1.0000
1:43956469:TG:T	donor_gain	1.0000
1:43956470:GG:G	donor_gain	1.0000
1:43957193:A:AG	acceptor_gain	1.0000
1:43957193:AG:A	acceptor_gain	1.0000
1:43957194:G:GG	acceptor_gain	1.0000
1:43957194:GG:G	acceptor_gain	1.0000
1:43957976:GGA:G	acceptor_gain	1.0000
1:43958108:TGC:T	donor_gain	1.0000
1:43958157:AGG:A	donor_loss	1.0000
1:43958158:GG:G	donor_loss	1.0000
1:43958159:GT:G	donor_loss	1.0000
1:43958458:CA:C	acceptor_loss	1.0000
1:43958459:A:AG	acceptor_gain	1.0000
1:43958459:A:C	acceptor_loss	1.0000
1:43958460:G:GT	acceptor_gain	1.0000
1:43958460:GA:G	acceptor_gain	1.0000
1:43958460:GAC:G	acceptor_gain	1.0000
1:43958460:GACA:G	acceptor_gain	1.0000

AlphaMissense

6291 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:43949430:T:C	L33P	1.000
1:43949478:T:A	L49Q	1.000
1:43949478:T:C	L49P	1.000
1:43949507:T:A	W59R	1.000
1:43949507:T:C	W59R	1.000
1:43949509:G:C	W59C	1.000
1:43949509:G:T	W59C	1.000
1:43949561:T:C	F77L	1.000
1:43949563:T:A	F77L	1.000
1:43949563:T:G	F77L	1.000
1:43949564:G:A	G78R	1.000
1:43949564:G:C	G78R	1.000
1:43949564:G:T	G78W	1.000
1:43949565:G:A	G78E	1.000
1:43949568:C:A	A79D	1.000
1:43949577:T:C	L82P	1.000
1:43949585:A:G	K85E	1.000
1:43949587:G:C	K85N	1.000
1:43949587:G:T	K85N	1.000
1:43949646:T:C	L105P	1.000
1:43949700:T:C	L123P	1.000
1:43950017:T:A	W229R	1.000
1:43950017:T:C	W229R	1.000
1:43956427:G:C	R310P	1.000
1:43956666:A:C	S357R	1.000
1:43956668:C:A	S357R	1.000
1:43956668:C:G	S357R	1.000
1:43956687:T:A	W364R	1.000
1:43956687:T:C	W364R	1.000
1:43956697:T:C	L367P	1.000

dbSNP variants (sampled 300 via entrez): RS1000323710 (1:43965150 G>T), RS1000807373 (1:43965185 T>G), RS1000859824 (1:43965517 C>A,T), RS1001196506 (1:43950393 A>G,T), RS1001350474 (1:43948696 G>T), RS1001426243 (1:43965663 C>G), RS1001540623 (1:43965300 A>G,T), RS1001800276 (1:43949101 G>A,C), RS1001870957 (1:43963606 C>G), RS1002554937 (1:43966992 T>A), RS1002662166 (1:43966054 G>A), RS1002758938 (1:43950443 T>A,G), RS1003142757 (1:43959775 T>C), RS1003383622 (1:43952668 GAT>G), RS1003541325 (1:43952337 T>C)

Disease associations

OMIM: gene MIM:610411 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004521_235	Autism spectrum disorder or schizophrenia	4.000000e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, affects cotreatment, affects expression, increases abundance	3
Aflatoxin B1	increases expression, increases methylation	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
decabromobiphenyl ether	decreases expression	1
tetrabromobisphenol A	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
(+)-JQ1 compound	increases expression	1
Resveratrol	increases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Calcitriol	decreases expression	1
Cisplatin	increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	increases expression, affects cotreatment	1
Oils, Volatile	increases abundance, affects cotreatment, affects expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Zearalenone	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.